Neuroprotective effects of the antiparkinson drug Mucuna pruriens

Phytotherapy Research

Volumn 18, Issue 9, 2004, Pages 706-712

  Manyam, Bala V ^a,c   Dhanasekaran, Muralikrishnan ^a   Hare, Theodore A ^b  

^a TEXAS A AND M UNIVERSITY SYSTEM   (United States)

^b MESSIAH COLLEGE   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

Author keywords

6 hydroxydopamine; Complex I activity; Mucuna pruriens; NADH and coenzyme Q 10; Neuroprotection; Nigrostriatal tract; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE; LEVODOPA; NEUROPROTECTIVE AGENT; NORADRENALIN; OXIDOPAMINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SEROTONIN; UBIDECARENONE; UNCLASSIFIED DRUG; VELVET BEAN EXTRACT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN MITOCHONDRION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; ENZYME ACTIVITY; MALE; NEUROCHEMISTRY; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; RAT; VELVET BEAN;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; LEVODOPA; MALE; MITOCHONDRIA; MUCUNA; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE; PHYTOTHERAPY; PLANT COMPONENTS, AERIAL; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY;

MUCUNA; MUCUNA PRURIENS;

EID: 8344282763     PISSN: 0951418X     EISSN: None     Source Type: Journal    
DOI: 10.1002/ptr.1514     Document Type: Article

References (35)

1. Basma AN, Morris EJ, Nicklas WJ, Geller HM. 1995. L-Dopa cytotoxicity to PC12 cells in culture is via its autoxidation. J Neurochem 64: 825-832.
2. Beal MF. 1998. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann Neurol 3: 110-114.
3. Beal MF, Matthews RT, Tieleman A, Shults CW. 1998. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res 783: 109-114.
4. Birkmayer GJ, Birkmayer W. 1989. Stimulation of endogenous L-dopa biosynthesis - a new principle for the therapy of Parkinson's disease. The clinical effect of nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotidephosphate (NADPH). Acta Neurol Scand Suppl 126: 183-187.
5. Birkmayer JG, Vrecko C, Volc D, Birkmayer W. 1993. Nicotinamide adenine dinucleotide (NADH) - a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application. Acta Neurol Scand 146: 32-35.
6. Birkmayer W, Birkmayer GJ, Vrecko K, Mlekusch W, Paletta B, Ott E. 1989. The coenzyme nicotinamide adenine dinucleotide (NADH) improves the disability of parkinsonian patients. J Neural Transm Park Dis Dement Sect 1: 297-302.
7. Birkmayer W, Birkmayer JG, Vrecko K, Paletta B. 1990. The clinical benefit of NADH as stimulator of endogenous L-dopa biosynthesis in parkinsonian patients. Adv Neurol 53: 545-549.
8. Calne DB, Teychenne PF, Claveria LE, Eastman R, Greenacre JK, Petne A. 1974. Bromocriptine in parkinsonism. Br Med J 4: 442-444.
9. Georgievska B, Kirik D, Rosenblad C, Lundberg C, Bjorklund A. 2002. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport 13: 75-82.
10. Gotz ME, Gerstner A, Harth R, et al. 2000. Altered redox state of platelet coenzyme Q10 in Parkinson's disease. J Neurol Trans 107: 41-48.
11. HP-200 in Parkinson's Disease Study Group. 1995. HP-200: An 'alternative medicine' treatment for Parkinson's disease. J Alternat Comp Med 1: 249-255.
12. Hussain G, Manyam BV. 1997. Mucuna pruriens proves more effective than L-DOPA in Parkinson's disease animal model. Phytother Res 11: 419-423.
13. Jenner P. 2001. Parkinson's disease, pesticides and mitochondrial dysfunction. Trends Neurosci 24: 245-257.
14. Kaakkola S, Teravainen H. 1990. Animal models of Parkinsonism. Pharmacol Toxicol 67: 95-100.
15. Langston JW, Forno LS, Rebert CS, Irwin I. 1984. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6- tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res 292: 390-394.
16. Mahajani SS, Doshi VJ, Parikh KM, Manyam BV. 1996. Bioavailability of L-DOPA from HP-200 - a formulation of seed powder of Mucuna pruriens (Bak): pharmacokinetic and pharmacodynamic study. Phytother Res 10: 254-256.
17. Manyam BV. 1990. Paralysis agitans and levodopa in 'Ayurveda', ancient Indian medical treatise. Movement Disord 5: 47-48.
18. Manyam BV, Dhanasekaran M, Hare T. 2004. Effect of anti-parkinson drug HP-200 (Mucuna pruriens) on the central monoaminergic neurotransmitters. Phytother Res 18: 97-101.
19. Matthews RT, Yang L, Browne S, Baik M, Beal MF. 1998. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci USA 95: 8892-8897.
20. Mohanakumar KP, Muralikrishnan D, Thomas B. 2000. Neuroprotection by salicylic acid against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced neurotoxicity. Brain Res 864: 281-290.
21. Morinan A, Garratt HM. 1985. An improved fluorimetric assay for brain monoamine oxidase. J Pharmacol Methods 13: 213-223.
22. Muralikrishnan D, Ebadi M. 2001. SKF-38393, a dopamine receptor agonist, attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Brain Res 892: 241-247.
23. Muralikrishnan D, Ray S, Mohanakumar KP. 2003. D-Deprenyl protects nigrostriatal neurones against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- induced dopaminergic neurotoxicity. Synapse 50: 7-13.
24. Murer MG, Dziewczapolski G, Menalled LB, et al. 1998. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 43: 561-575.
25. Naudin B, Bonnet JJ, Costentin J. 1995. Acute L-DOPA pretreatment potentiates 6-hydroxydopamine-induced toxic effects on nigro-striatal dopamine neurons in mice. Brain Res 701: 151-157.
26. Perese DA, Ulman J, Viola J, Ewing SE, Bankiewicz KS. 1989. A 6-hydroxydopamine-induced selective parkinsonian rat model. Brain Res 494: 285-293.
27. Ramsay RR, Salach JI, Dadgar J, Singer TP. 1986. Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. Biochem Biophys Res Commun 135: 269-275.
28. Riess O, Kruger R. 1999. Parkinson's disease - a multifactorial neurodegenerative disorder. J Neural Transm 56: 113-125.
29. Rousseau G, Varin F. 1988. Determination of ubiquinone-9 and 10 levels in rat tissues and blood by high performance liquid chromatography with ultraviolet detection. J Chromatogr 36: 247-252.
30. Schmidt N, Ferger B. 2001. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease. Synapse 40: 47-54.
31. Shults CW, Haas RH, Passov D, Beal MF. 1997. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol 42: 261-264.
32. Smith TS, Parker WD Jr, Bennett JP Jr. 1994. L-Dopa increases nigral production of hydroxyl radicals in vivo: potential L-dopa toxicity? Neuroreport 5: 1009-1011.
33. Stern N, Hochman A, Zemach N, et al. 2002. Accumulation of DNA damage and reduced levels of nicotine adenine dinucleotide in the brains of Atm-deficient mice. J Biol Chem 277: 602-608.
34. Tripathi YB, Upadhyay AK. 2002. Effect of the alcohol extract of the seeds of Mucuna pruriens on free radicals and oxidative stress in albino rats. Phytother Res 16: 534-538.
35. Ungerstedt U, Arbuthnott GW. 1970. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 24: 485-493.